These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8839165)

  • 1. IL12 as an adjuvant for vaccines designed to prevent infection and immunopathology by schistosomes.
    Wynn TA; Sher A
    Res Immunol; 1995; 146(7-8):582-90. PubMed ID: 8839165
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukins and colon cancer.
    Caro-Patón Gómez A
    Rev Esp Enferm Dig; 2005 Sep; 97(9):613-8. PubMed ID: 16266233
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of recombinent interleukin-12 as an adjuvant on vaccine-induced immunity in murine Schistosoma mansoni infection.
    Abdel-Aaty HE; Ramadan NI; Mahmoud MS; Abdel-Aziz SS; Khalil HM; El-Badawy NM; Khalil HH
    J Egypt Soc Parasitol; 1999; 29(1):1-11. PubMed ID: 12561877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an antipathology vaccine for schistosomiasis.
    Wynn TA
    Ann N Y Acad Sci; 1996 Oct; 797():191-5. PubMed ID: 8993362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination against Schistosoma mansoni infection using 74 kDa Schistosoma protein antigen.
    Attallah AM; Attia H; Ismail H; Yones E; El-Nashar EM; Abd El-Kader K; Tabll A; Saad A; Sultan A
    Vaccine; 1999 Jul; 17(22):2786-91. PubMed ID: 10438048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of IL12 as an anti-tumour agent: current status and future directions.
    Brunda MJ
    Res Immunol; 1995; 146(7-8):622-28. PubMed ID: 8839170
    [No Abstract]   [Full Text] [Related]  

  • 7. [Role of interleukin-12 in cancer immunotherapy].
    Mazzolini G; Melero I; Prieto J
    Medicina (B Aires); 2004; 64(1):77-8. PubMed ID: 15034963
    [No Abstract]   [Full Text] [Related]  

  • 8. Vaccination of mice with a 30 kDa Schistosoma antigen with and without human adjuvant induces high protection against S. mansoni infection.
    Attallah AM; Abdel Aziz MM; Abbas AT; Elbakry KA; El-Sharabasy MM
    J Helminthol; 2004 Sep; 78(3):189-94. PubMed ID: 15469619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-gamma, IL-12, and TNF-alpha are required to maintain reduced liver pathology in mice vaccinated with Schistosoma mansoni eggs and IL-12.
    Hoffmann KF; Caspar P; Cheever AW; Wynn TA
    J Immunol; 1998 Oct; 161(8):4201-10. PubMed ID: 9780194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL12.
    Parney IF; Farr-Jones MA; Kane K; Chang LJ; Petruk KC
    Can J Neurol Sci; 2002 Aug; 29(3):267-75. PubMed ID: 12195617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoclaved cercarial vaccine: a new hope against schistosomiasis parasitologic, histopathologic and immunologic studies.
    Eissa MM; Allam SR; el Azzouni MZ; Baddour NM
    J Egypt Soc Parasitol; 1998 Aug; 28(2):461-79. PubMed ID: 9707675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant.
    Mountford AP; Anderson S; Wilson RA
    J Immunol; 1996 Jun; 156(12):4739-45. PubMed ID: 8648120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application.
    Zitvogel L; Lotze MT
    Res Immunol; 1995; 146(7-8):628-38. PubMed ID: 8839171
    [No Abstract]   [Full Text] [Related]  

  • 14. Protective capacity of cercarial transformation fluid alone or in combination with crude cercarial antigen against challenge infections of Schistosoma mansoni in mice.
    El Azzouni MZ; Mady RF; Gaafar MR; Arafa FM; Elhadidi A
    J Helminthol; 2017 Jan; 91(1):35-42. PubMed ID: 26817577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An IL-12-based vaccine approach for preventing immunopathology in schistosomiasis.
    Sher A; Jankovic D; Cheever A; Wynn T
    Ann N Y Acad Sci; 1996 Oct; 795():202-7. PubMed ID: 8958931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-12 at the crossroads.
    Hall SS
    Science; 1995 Jun; 268(5216):1432-4. PubMed ID: 7770767
    [No Abstract]   [Full Text] [Related]  

  • 17. Proteosome delivery of a protective 9B-antigen against Schistosoma mansoni.
    Tarrab-Hazdai R; Schechtman D; Lowell G; Pirak E; Arnon R
    Int J Immunopharmacol; 1999 Mar; 21(3):205-18. PubMed ID: 10348370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attempts to induce resistance in mice to Schistosoma japonicum and Schistosoma mansoni by exposure to crude schistosome antigens plus cloned glutathione-S-transferases.
    Mitchell GF; Davern KM; Wood SM; Wright MD; Argyropoulos VP; McLeod KS; Tiu WU; Garcia EG
    Immunol Cell Biol; 1990 Dec; 68 ( Pt 6)():377-85. PubMed ID: 2129038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of non-specific immunopotentiators in experimental Schistosoma mansoni infection. II. Corynebacterium parvum.
    Teixeira KM; Coutinho EM; Abath FG; Montenegro SM
    Rev Inst Med Trop Sao Paulo; 1996; 38(5):359-63. PubMed ID: 9293078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-12 as adjuvant in peptide vaccines.
    O'Toole M; Wooters J; Brown E; Swiniarski H; Cull G; Leger L; Herrmann S
    Ann N Y Acad Sci; 1996 Oct; 795():379-81. PubMed ID: 8958960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.